Aigen Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Aigen Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,823	Closed	-$228K	–	981
2024 Q3	$228K	Sell	1,823 -7,994	-81%	-$1.11M	0.04%	541
2024 Q2	$1.55M	Buy	9,817 +8,106	+474%	+$1.04M	0.3%	81
2024 Q1	$222K	Sell	1,711 -1,560	-48%	-$191K	0.05%	521
2023 Q4	$315K	Buy	+3,271	New	+$314K	0.06%	467
2023 Q3	–	Sell	-4,428	Closed	-$507K	–	1073
2023 Q2	$507K	Sell	4,428 -8,428	-66%	-$1.09M	0.07%	345
2023 Q1	$1.77M	Sell	12,856 -5,606	-30%	-$727K	0.24%	105
2022 Q4	$2.39M	Buy	18,462 +6,608	+56%	+$766K	0.34%	80
2022 Q3	$1.31M	Buy	+11,854	New	+$1.19M	0.19%	157
2022 Q2	–	Sell	-3,209	Closed	-$251K	–	710
2022 Q1	$251K	Buy	+3,209	New	+$246K	0.04%	427
2021 Q2	–	Sell	-18,621	Closed	-$1.39M	–	718
2021 Q1	$1.39M	Buy	+18,621	New	+$1.72M	0.18%	134
2020 Q4	–	Sell	-2,972	Closed	-$417K	–	1029
2020 Q3	$417K	Buy	+2,972	New	+$452K	0.05%	441

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aigen Investment Management's SRPT Position: Q4 2024 in Review

Aigen Investment Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 1,823 shares — an estimated $228K sold.

Aigen Investment Management first reported a position in SRPT in Q3 2020 and held it in 11 quarters. The position peaked at $2.39M in Q4 2022. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Aigen Investment Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Aigen Investment Management sold 1,823 Sarepta Therapeutics shares in Q4 2024, an estimated $228K.
Aigen Investment Management first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 11 quarters.
Aigen Investment Management's Sarepta Therapeutics position peaked at $2.39M in Q4 2022.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Aigen Investment Management's 13F filing for Q4 2024, filed 6 Feb 2025.